Stock Track | Viatris Stock Soars 15% as Q3 Results Beat Estimates on Strong New Drug Sales

Stock Track

2024-11-08

Shares of Viatris Inc. (VTRS) soared 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by robust demand for its newly launched generic drugs.

For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, slightly ahead of the consensus forecast of $3.71 billion.

The company's impressive performance was driven by strong sales of its recently introduced generic versions of popular drugs like AstraZeneca's asthma inhaler Symbicort and Takeda's ADHD medication Vyvanse. Revenue from new product launches totaled $133 million in the third quarter, contributing significantly to the overall revenue beat.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1156794825"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1156794825\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1156794825?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 12:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156794825","market":"hk","top_or_hot":-1,"title":"Stock Track | Viatris Stock Soars 15% as Q3 Results Beat Estimates on Strong New Drug Sales","media":"Stock Track","content":"<p>Shares of Viatris Inc. (VTRS) soared 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by robust demand for its newly launched generic drugs.</p>\n\n<p>For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, slightly ahead of the consensus forecast of $3.71 billion.</p>\n\n<p>The company's impressive performance was driven by strong sales of its recently introduced generic versions of popular drugs like AstraZeneca's asthma inhaler Symbicort and Takeda's ADHD medication Vyvanse. Revenue from new product launches totaled $133 million in the third quarter, contributing significantly to the overall revenue beat.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Viatris Stock Soars 15% as Q3 Results Beat Estimates on Strong New Drug Sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Viatris Stock Soars 15% as Q3 Results Beat Estimates on Strong New Drug Sales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-11-08 12:40</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Viatris Inc. (VTRS) soared 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by robust demand for its newly launched generic drugs.</p>\n\n<p>For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, slightly ahead of the consensus forecast of $3.71 billion.</p>\n\n<p>The company's impressive performance was driven by strong sales of its recently introduced generic versions of popular drugs like AstraZeneca's asthma inhaler Symbicort and Takeda's ADHD medication Vyvanse. Revenue from new product launches totaled $133 million in the third quarter, contributing significantly to the overall revenue beat.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTRS","symbol_name":"Viatris Inc.","start_time":0,"source_url":"","article_id":"1156794825","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156794825","pubTimestamp":1731040851,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Viatris Inc.  soared 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by robust demand for its newly launched generic drugs.For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, slightly ahead of the consensus forecast of $3.71 billion.The company's impressive performance was driven by str","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTRS":"Viatris Inc."},"translate_title":"股票轨迹Viatris股价飙升15%，第三季度业绩超出预期，新药销售强劲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":1},"content_text":"Shares of Viatris Inc. (VTRS) soared 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by robust demand for its newly launched generic drugs.\nFor the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, slightly ahead of the consensus forecast of $3.71 billion.\nThe company's impressive performance was driven by strong sales of its recently introduced generic versions of popular drugs like AstraZeneca's asthma inhaler Symbicort and Takeda's ADHD medication Vyvanse. Revenue from new product launches totaled $133 million in the third quarter, contributing significantly to the overall revenue beat.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}